RXDX Prometheus Biosciences Inc.

22.91
+0.21  (+1%)
Previous Close 22.7
Open 23.68
52 Week Low 16.11
52 Week High 28.33
Market Cap $887,860,555
Shares 38,754,280
Float 29,883,890
Enterprise Value $832,920,156
Volume 166,060
Av. Daily Volume 159,505
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
PRA023
Ulcerative colitis
Phase 1a
Phase 1a
Phase 1a trial initiated December 2020.

Latest News

  1. SAN DIEGO, March 16, 2021 /PRNewswire/ -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD), today announced the closing of its initial public offering of 11,500,000 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,500,000 additional shares, at a public offering price of $19.00 per share. All of the shares were offered by Prometheus. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses…

    SAN DIEGO, March 16, 2021 /PRNewswire/ -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD), today announced the closing of its initial public offering of 11,500,000 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,500,000 additional shares, at a public offering price of $19.00 per share. All of the shares were offered by Prometheus. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Prometheus, were $218.5 million. Prometheus' common stock is listed on the Nasdaq Global Select Market under the ticker symbol "RXDX".

    SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities acted as joint bookrunning managers for the offering.

    Registration statements relating to the offering have been filed with the Securities and Exchange Commission (SEC) and became effective on March 11, 2021. A prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's website at www.sec.gov. The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525, ext. 6105, or by email at ; or from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, or by telephone at (800) 221-1037, or by email at ; or from Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, Attn: Syndicate, or by phone at (415) 364-2720 or by email at ; or from Guggenheim Securities LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-5548 or by email at .

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

    About Prometheus Biosciences

    Prometheus Biosciences, Inc. is a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD. The company's precision medicine platform, Prometheus360, combines proprietary bioinformatics discovery methods with one of the world's largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. 

    Prometheus is headquartered in San Diego, CA. 

     

    Cision View original content:http://www.prnewswire.com/news-releases/prometheus-biosciences-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-301248704.html

    SOURCE Prometheus Biosciences

    View Full Article Hide Full Article
  2. SAN DIEGO, March 11, 2021 /PRNewswire/ -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD), today announced the pricing of its upsized initial public offering of 10,000,000 shares of common stock at a public offering price of $19.00 per share. All of the shares are being offered by Prometheus. The shares are expected to begin trading on the Nasdaq Global Select Market on March 12, 2021 under the ticker symbol "RXDX". The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering…

    SAN DIEGO, March 11, 2021 /PRNewswire/ -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD), today announced the pricing of its upsized initial public offering of 10,000,000 shares of common stock at a public offering price of $19.00 per share. All of the shares are being offered by Prometheus. The shares are expected to begin trading on the Nasdaq Global Select Market on March 12, 2021 under the ticker symbol "RXDX". The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Prometheus, are expected to be $190 million. The offering is expected to close on March 16, 2021, subject to satisfaction of customary closing conditions. In addition, Prometheus has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

    SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities are acting as joint bookrunning managers for the offering.

    Registration statements relating to the offering have been filed with the Securities and Exchange Commission and became effective on March 11, 2021. The offering will be made only by means of a prospectus. When available, copies of the prospectus may be obtained from SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525, ext. 6105, or by email at ; or from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, or by telephone at (800) 221-1037, or by email at ; or from Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, Attn: Syndicate, or by phone at (415) 364-2720 or by email at ; or from Guggenheim Securities LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-5548 or by email at .

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

    About Prometheus Biosciences

    Prometheus Biosciences, Inc. is a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD. The company's precision medicine platform, Prometheus360, combines proprietary bioinformatics discovery methods with one of the world's largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. 

    Prometheus is headquartered in San Diego, CA. 

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering-301246163.html

    SOURCE Prometheus Biosciences

    View Full Article Hide Full Article
View All Prometheus Biosciences Inc. News